WCM
NMRA icon

Wildcat Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Wildcat Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-54,894
Closed -$755K – 19
2024
Q1 		$755K Buy
+54,894
New +$887K 0.27% 15

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wildcat Capital Management's NMRA Position: Q2 2024 in Review

Wildcat Capital Management sold out of Neumora Therapeutics (NMRA) in Q2 2024, closing a stake of 54,894 shares — an estimated $755K sold.

Wildcat Capital Management first reported a position in NMRA in Q1 2024 and held it in 1 quarter. The position peaked at $755K in Q1 2024. 93 funds tracked by Wall St. Rank hold NMRA as of Q2 2024.

  • Wildcat Capital Management reported no remaining Neumora Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Wildcat Capital Management sold 54,894 Neumora Therapeutics shares in Q2 2024, an estimated $755K.
  • Wildcat Capital Management first reported a position in Neumora Therapeutics in Q1 2024 and held it in 1 quarter.
  • Wildcat Capital Management's Neumora Therapeutics position peaked at $755K in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2024.

Based on Wildcat Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.